Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiac Pharmacodynamics of Amiselimod in Healthy Subjects
NCT02193217Phase 1Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of amiselimod in relapsing-remitting multiple sclerosis (RRMS) (4 arms), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoint: Mean hourly heart rate. Status: completed.
02
Drugs
amiselimod
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT02193217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02193217.